BR112023023493A2 - BENZOYLGUANIDINE DERIVATIVE AND METHOD OF PREPARATION AND USE THEREOF - Google Patents

BENZOYLGUANIDINE DERIVATIVE AND METHOD OF PREPARATION AND USE THEREOF

Info

Publication number
BR112023023493A2
BR112023023493A2 BR112023023493A BR112023023493A BR112023023493A2 BR 112023023493 A2 BR112023023493 A2 BR 112023023493A2 BR 112023023493 A BR112023023493 A BR 112023023493A BR 112023023493 A BR112023023493 A BR 112023023493A BR 112023023493 A2 BR112023023493 A2 BR 112023023493A2
Authority
BR
Brazil
Prior art keywords
preparation
benzoylguanidine derivative
benzoylguanidine
derivative
pdes
Prior art date
Application number
BR112023023493A
Other languages
Portuguese (pt)
Inventor
Chunxia Li
De Wang
Guangli Yu
Haihua Li
Huashi Guan
Jiejie Hao
Yan Zhang
Original Assignee
Univ China Ocean
Qingdao Marine Biopharmaceutical Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ China Ocean, Qingdao Marine Biopharmaceutical Res Institute filed Critical Univ China Ocean
Publication of BR112023023493A2 publication Critical patent/BR112023023493A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

derivado de benzoilguanidina e método de preparação e uso do mesmo. na presente invenção são fornecidos um derivado de benzoilguanidina e um método de preparação e uso do mesmo. o derivado de benzoilguanidina possui um método de preparação simples, tem o efeito de inibir significativamente a atividade das fosfodiesterases (pdes), a liberação de tnf-a e o aumento de neutrófilos e eosinófilos, também pode proteger as células nervosas, cardiomiócitos e células endoteliais vasculares, possui uma boa segurança e, portanto, também possui um significado importante para o desenvolvimento.benzoylguanidine derivative and method of preparation and use thereof. In the present invention, a benzoylguanidine derivative and a method of preparing and using the same are provided. benzoylguanidine derivative has a simple preparation method, has the effect of significantly inhibiting the activity of phosphodiesterases (pdes), the release of tnf-a and the increase of neutrophils and eosinophils, it can also protect nerve cells, cardiomyocytes and endothelial cells vascular, has good safety and therefore also has important developmental significance.

BR112023023493A 2021-05-10 2022-05-10 BENZOYLGUANIDINE DERIVATIVE AND METHOD OF PREPARATION AND USE THEREOF BR112023023493A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110505150.8 2021-05-10
PCT/CN2022/092035 WO2022237798A1 (en) 2021-05-10 2022-05-10 Benzoylguanidine derivative, and preparation method therefor and use thereof

Publications (1)

Publication Number Publication Date
BR112023023493A2 true BR112023023493A2 (en) 2024-01-30

Family

ID=83931615

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023493A BR112023023493A2 (en) 2021-05-10 2022-05-10 BENZOYLGUANIDINE DERIVATIVE AND METHOD OF PREPARATION AND USE THEREOF

Country Status (3)

Country Link
CN (2) CN115317474A (en)
BR (1) BR112023023493A2 (en)
WO (1) WO2022237798A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1095933A1 (en) * 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
CN1915292A (en) * 2006-09-10 2007-02-21 郝书平 Application of acetylcholine esterase inhibitor medication of Yidancao extractive as cholinomimetic
CN102001971B (en) * 2010-11-19 2013-01-02 安徽中医学院 N-(4-guanidyl butyl) syringoylagmatine derivatives and pharmaceutical applications thereof
CN102475699A (en) * 2010-11-26 2012-05-30 复旦大学 Application of leonurine in preparation of medicines used for preventing and treating parkinson disease
CN102579420A (en) * 2011-01-17 2012-07-18 复旦大学 Application of leonurine to preparation of medicament for treating 2-type diabetes
CN103450059A (en) * 2012-06-02 2013-12-18 复旦大学 Mercaptoethylguanidine derivative, and its use in pharmacy

Also Published As

Publication number Publication date
WO2022237798A1 (en) 2022-11-17
CN115317474A (en) 2022-11-11
CN115504909A (en) 2022-12-23

Similar Documents

Publication Publication Date Title
AR055435A1 (en) ADMINISTATION OF DIPEPTIDIL PEPTIDASA INHIBITORS
BR112021012635A2 (en) 3-Carbonylamino-5-cyclopentyl-1fi-pyrazole compounds having inhibitory activity on cdk2
BR112018007982A2 (en) composition, enzymatic reaction and method for preparing a graft copolymer
BR112013024907A2 (en) compound, pharmaceutical composition, method for treating, preventing or attenuating one or more symptoms of a pi3k-mediated disorder, disease or condition in a subject, method for modulating pi3k enzymatic activity
BR112017023380A2 (en) system, cosmetic composition, methods for treating keratinous substrates and for hair fiber protection and / or straightening, multi-compartment kit, and hair straightening process.
BR112015011158A8 (en) triazolopyrazine, its use and pharmaceutical preparation
ECSP20025070A (en) TRISPECIFIC PROTEINS AND METHODS OF USE
BR112018002168A2 (en) nicotinamide mononucleotide derivatives and their uses
BR112012027062B8 (en) compost, process for preparing a compost and uses thereof
BR112016002753A2 (en) antibodies to plasminogen activator inhibitor-1 (parent-1) and uses thereof
BR112014027181A2 (en) benzamide derivatives for inhibition of abl1, abl2 and bcr-abl1 activity
BR112012030818A2 (en) "modified c-3 betulinic acid derivatives as inhibitors of hiv maturation"
BRPI0919873B8 (en) substituted pyrazol[1,5-a]pyrimidine compounds as trk kinase inhibitors, their preparation processes and pharmaceutical compositions
CL2011000489A1 (en) Compounds derived from pyrimido [5,4-d] pyrimidine, which act as tyrosine kinase inhibitors; and pharmaceutical compositions that comprise them, useful in the treatment of diseases characterized by excessive or abnormal cell proliferation
BRPI1011838B8 (en) heterocyclic diamino carboxamide compounds, their use, pharmaceutical composition comprising them and inhibitor against eml4-alk fusion protein kinase activity
BRPI0819719B8 (en) dipeptidyl peptidase-iv inhibiting compounds, methods of preparation thereof, and pharmaceutical preparations containing them as active agent
BR112013001270A2 (en) artificial cellulosome and its use for enzymatic degradation of resilient substrates.
BR112014018524A8 (en) PYRIMID [4,5-B]INDOL DERIVATIVES, THEIR USES, PHARMACEUTICAL COMPOSITION, AND IN VIVO OR EX VIVO METHOD TO INCREASE STEM AND/OR PROGENITOR CELLS
MX362442B (en) Ire-1-alpha inhibitors.
BR112014006176A8 (en) IN VITRO TRANSCRIBED RNA OR SYNTHETIC RNA, COMPOSITION, METHOD FOR GENERATING AN RNA GENETICALLY MODIFIED T CELL POPULATION, AND, USE OF A GENETICALLY MODIFIED T CELL
CA2816976A1 (en) Optogenetic control of reward-related behaviors
BR112014007622A2 (en) macrocyclic flt3 kinase inhibitors
BR112014027117A8 (en) PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS, THEIR USES, AND COMPOSITION
BR112012000914B8 (en) use of polypeptide with chondrogenic activity, in vitro method of inducing differentiation of mesenchymal stem cells into chondrocytes, and pharmaceutical composition for intra-articular application
BR112022001324A2 (en) Compound, pharmaceutical composition and method for treating a p38 map kinase-mediated disease in a subject in need thereof